Coya Therapeutics (NASDAQ:COYA) Given "Buy" Rating at BTIG Research

Key Points

• BTIG Research reiterated a “Buy” rating on Coya Therapeutics and set a $16 price target, implying 246.7% upside from the prior close.
• Analyst sentiment is generally positive: six analysts rate the stock Buy and one rates it Sell, producing a consensus “Moderate Buy” rating and an average target of $15.33.
• Coya shares fell 0.5% to $4.62, while the company reported a quarterly loss of $0.28 per share—better than the $0.35 estimate—and revenue of $0.24 million.

Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "buy" rating restated by equities researchers at BTIG Research in a research note issued on Tuesday, Benzinga reports. They presently have a $16.00 price objective on the stock. BTIG Research's price objective would suggest a potential upside of 246.70% from the stock's previous close.

COYA has been the subject of a number of other research reports. Chardan Capital restated a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a research note on Wednesday, August 12th. Weiss Ratings restated a "sell (d-)" rating on shares of Coya Therapeutics in a report on Friday, July 17th. Roth Capital reiterated a "buy" rating and set a $12.00 target price on shares of Coya Therapeutics in a report on Monday, August 24th. Finally, HC Wainwright reissued a "buy" rating on shares of Coya Therapeutics in a research report on Monday, August 24th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $15.33.

Coya Therapeutics Stock Down 0.5%

Shares of NASDAQ:COYA traded down $0.03 on Tuesday, hitting $4.62. The company had a trading volume of 101,731 shares, compared to its average volume of 181,283. The firm's 50-day simple moving average is $4.66 and its two-hundred day simple moving average is $4.66. The firm has a market capitalization of $108.26 million, a price-to-earnings ratio of -4.29 and a beta of 0.61. Coya Therapeutics has a 1 year low of $3.71 and a 1 year high of $7.75.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.07. Coya Therapeutics had a negative net margin of 270.22% and a negative return on equity of 52.05%. The company had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.13 million. Equities research analysts anticipate that Coya Therapeutics will post -1.34 EPS for the current year.

Institutional Trading of Coya Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Allworth Financial LP raised its holdings in shares of Coya Therapeutics by 1,200.0% during the second quarter. Allworth Financial LP now owns 13,000 shares of the company's stock valued at $76,000 after purchasing an additional 12,000 shares during the last quarter. AXQ Capital LP purchased a new stake in Coya Therapeutics during the 2nd quarter valued at $116,000. Long Corridor Asset Management Ltd purchased a new position in shares of Coya Therapeutics in the 2nd quarter worth $227,000. ADAR1 Capital Management LLC bought a new stake in shares of Coya Therapeutics in the first quarter worth $161,000. Finally, Renaissance Technologies LLC increased its position in Coya Therapeutics by 55.4% during the first quarter. Renaissance Technologies LLC now owns 103,964 shares of the company's stock valued at $410,000 after acquiring an additional 37,064 shares during the last quarter. Hedge funds and other institutional investors own 39.75% of the company's stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc NASDAQ: COYA is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company's scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya's pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.